TEVA•benzinga•March 27, 2025 at 08:35 PM

Teva Pharmaceutical Sees FY25 EPS $2.35-$2.65 Vs $2.58 Est.; Revenue $16.8B-$17.4B Vs $17.10B Est.; Sees First Half Of 2025 Revenues Are Expected To Be Slightly Lower Than Second Half Of 2025 Revenues, With Q1 Revenues Expected To Be Lower Than Q2 Revenue

No summary available.

Read the full article from the original source for complete details and context.

Article published on March 27, 2025 by benzinga